In vivo antitumor activity of bropirimine against PAIII and dunning MAT-LyLu rodent prostate cancers

Journal of Urology

Volumn 155, Issue 6, 1996, Pages 2085-2089

  Sarosdy, Michael F ^a,b   Higdon, Arlene L ^a   Demoor, Carl A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Division of Urology   (United States)

Author keywords

Immunotherapy; Prostatic neoplasms

Indexed keywords

BROPIRIMINE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; INTRAGASTRIC DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOSINE; MALE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RATS; RATS, INBRED STRAINS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0029924112     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66114-7     Document Type: Article

References (20)

1. Trachtenberg, J.: Hormonal management of stage D carcinoma of the prostate. Urol. Clin. North Am., 14: 684, 1987.
2. Crawford, E. D. and Nabors, W. L.: Total androgen ablation: American experience. Urol. Clin. North Am., 18: 55, 1991.
3. Eisenberger, M. A., Bezerdjian, L. and Kalash, S.: A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma. Urol. Clin. North Am., 14: 695, 1987.
4. Lotzova, E., Savary, C. A., Khan, A. and Stringfellow, D. A.: Stimulation of natural killer cells in two random-bred strains of athymic rats by interferon-inducing pyrimidinone. J. Immunol., 132: 2566, 1984.
5. Eggermont, A. M. M., Marquet, R. L., de Bruin, R. W. F. and Jeekel, J.: Effects of the interferon-inducer ABPP on colon cancer in rats: importance of tumor load and tumor site. Cancer Immunol. Immunother., 22: 217, 1986.
6. Wierenga, W.: Antiviral and other bioactivities of pyrimidinones. Pharmacol. Ther., 30: 67, 1985.
7. Sarosdy, M. F., Lamm, D. L., Williams, R. D., Moon, T. D., Flanigan, R. C., Crawford, E. D., Wilks, N. E., Earhart, R. H. and Merritt, J. A.: Phase I trial of oral bropirimine in superficial bladder cancer. J. Urol., 147: 31, 1992.
8. Sarosdy, M. F., Lowe, B. A., Schellhammer, P. F., Lamm, D. L., Graham, S. D., Grossman, H. B., See, W. A., Peabody, J. O., Moon, T. D., Flanigan, R. C., Crawford, E. D. and Earhart, R. H.: Bropirimine immunotherapy of bladder CIS: positive phase II results of an oral interferon inducer. J. Urol., 151: 304A, 1994.
9. Isaacs, J. T.: Development and characteristics of the available animal model systems for the study of prostatic cancer. In: Current Concepts and Approaches to the Study of Prostate Cancer. Edited by D. S. Coffey. New York: A. R. Liss, p. 513, 1987.
10. Sarosdy, M. F. and Kierum, C. A.: Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone. J. Urol., 142: 1376, 1989.
11. Sidkey, Y. A., Borden, E. C., Wierenga, W. and Bryan, G. T.: Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors. Cancer Res., 46: 3798, 1986.
12. Simmons, W. B., Reichert, D. F., Lucio, R. M. and Lamm, D. L.: Pyrimidinone interferon inducers in the treatment of murine transitional cell carcinoma. J. Urol., part 2, 129A: 169, 1983.
13. Guinan, P., Toronchi, E., Shaw, M., Crispin, R. and Sharifi, R.: Bacillus Calmette-Guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology, 20: 401, 1982.
14. Sherwood, E. R., Ford, T. R., Lee, C. and Kozlowski, J. M.: Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. J. Biol. Response Mod., 9: 44, 1990.
15. Webb, K. S., Lieberman, S. N., Ware, J. L. and Walther, P. J.: In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma. Cancer Immunol. Immunother., 21: 100, 1986.
16. Omarbasha, B., Fair, W. R. and Heston, W. D.: Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma. Cancer Res., 49: 3045, 1989.
17. von Angerer, E., Kager, M. and Maucher, A.: Antitumor activity of coumarin in prostate and mammary cancer models. J. Cancer Res. Clin. Oncol., 120: S14, 1994.
18. Mohler, J. L., Williams, B. T. and Thompson, I. M.: Coumarin (1.2-benzopyrone) for the treatment of prostatic carcinoma. J. Cancer Res. Clin. Oncol., 120: S35, 1994.
19. Vieweg, J., Rosenthal, F. M., Bannerji, R., Heston, W. D., Fair, W. R., Gansbacher, B. and Gilboa, E.: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res., 54: 1760, 1994.
20. Sanda, M. G., Ayyagari, S. R., Jaffee, E. M., Epstein, J. I., Clift, S. L., Cohen, L. K., Dranoff, G., Pardoll, D. M., Mulligan, R. C. and Simons, J. W.: Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol., 151: 622, 1994.